ImmunoPrecise and Biotheus partner on bispecific antibodies to treat cancer
ImmunoPrecise Antibodies, an AI-driven biotherapeutic research and technology company, has entered into a material transfer and evaluation agreement (MTEA) with Biotheus on bispecific antibodies to treat cancer.

What's Your Reaction?






